Navigation Links
Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
Date:6/15/2010

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of the drugs in Isis' pipeline.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2009 and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.  

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a ... and genetic deficiencies that result in metabolic disorders, announced ... Form S-1 with the U.S. Securities and Exchange Commission ... shares of its common stock. The number of shares ... offering have not yet been determined. Citigroup ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... materials that are readily decomposed by the ... conventional non-degradable packaging in terms of raw ...
(Date:8/27/2014)... is how plants survive impact by the huge ... while using this energy for photosynthesis. The hypothesis ... blades quickly dissipate the energy throughout the entire ... DTU Physics have now managed to successfully ,film, ... contain light-absorbing proteins which play a role in ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Chelating Agents Market ... About Chelating Agent A chelating agent is ... with metal ions, thereby forming a metal-ion complex. ... have on chemical processes, formulations, and the environment ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7DTU researchers film protein quake for the first time 2Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4
... (Santa Barbara, Calif.) A team of physicists at UC ... many different colors. By aiming high- and low-frequency laser beams ... from their cores, accelerated, and then smashed back into the ... light simultaneously. Their findings appear in the current issue of ...
... 2012  Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology ... of patented technologies in the field of transplantation ... its subsidiary DiaKine Therapeutics Inc. received European patent ... be used to treat diabetes, atherosclerosis and other ...
... RIDGE, N.J., March 28, 2012  Regado Biosciences, Inc., a ... with active control agents, announced that David J. Mazzo, ... & Company,s 11th Annual Healthcare Conference at 10 a.m. ... Palace Hotel in New York City. The ...
Cached Biology Technology:UCSB Physicists mix 2 lasers to create light at many frequencies 2UCSB Physicists mix 2 lasers to create light at many frequencies 3Islet Sciences Announces DiaKine Therapeutics' Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection 2Islet Sciences Announces DiaKine Therapeutics' Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection 3Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 2Regado Biosciences, Inc. to Present at Needham & Company's 11th Annual Healthcare Conference in New York, NY 3
(Date:8/28/2014)... measuring and imaging how quickly blood flows in the ... drug abuse affects the brain, which may aid in ... better treatment options for recovering drug addicts. The new ... Brook University in New York, USA and the U.S. ... Optical Society,s (OSA) open-access journal Biomedical Optics ...
(Date:8/28/2014)... news release is available in German . ... products are now built with the help of sophisticated assembly ... fixed, are an important part of these assembly lines. In ... attached in various work stages arranged in a precise spatial ... end of the line. , The creation of such an ...
(Date:8/28/2014)... exports from Washington, Oregon, northern California, and Alaska totaled ... quarter of 2014, an increase of more than 10 ... U.S. Forest Service,s Pacific Northwest Research Station reported today. ... by 4 percent to 247 million board feet. , ... more than 5 percent to $390 million in the ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Nanoscale assembly line 2Nanoscale assembly line 3West coast log exports up, lumber exports down in second quarter of 2014 2
... of microbiologists has revealed a new concern about deforestation ... in the diversity among the microbial organisms responsible for ... The University of Texas at Arlington, University of Oregon, ... Sao Paulo, sampled a 100 square kilometer area, about ...
... today announced its ARGUS Whole Genome Mapping System ... to produce the first, high-quality reference genome of the ... and Kunming Institute of Zoology, Chinese Academy of Sciences ... The paper, titled Sequencing and automated whole-genome optical ...
... 2012, Shenzhen, China In a collaborative study published ... Kunming Institute of Zoology, Chinese Academy of Sciences, BGI, ... of domestic goat by a robust approach integrated with ... goat genome is the first reference genome for small ...
Cached Biology News:Deforestation in the Amazon equals net losses of diversity for microbial communities 2Deforestation in the Amazon equals net losses of diversity for microbial communities 3OpGen announces sequence assembly and finishing of first reference genome of domestic goat 2The first goat genome sets a good example for facilitating de novo assembly of large genomes 2The first goat genome sets a good example for facilitating de novo assembly of large genomes 3
... Assay Kit (E-22013) provides,researchers with a ... lysozyme,activity in solution. This fluorescence-based assay ... U/mL (Figure 1). The assay,measures lysozyme ... are labeled to such a degree ...
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... (Cap Analog) is used for the synthesis ... vitro transcription reactions. Substitution of cap analog ... in an in vitro transcription reaction results ... into a large fraction of the transcripts. ...
... iEMS Incubator/Shaker HT is designed ... iEMS Incubator/Shaker HT is ideal ... hybridization and primer extension assays. ... as a one-cabinet model, allowing ...
Biology Products: